Blake A. Morrison on Infusion Reactions With New Agents for Multiple Myeloma
Blake A. Morrison, PharmD, vice president, Medical and Scientific Affairs, Multiple Myeloma Research Foundation, discusses adverse events associated with new agents to treat patients with multiple myeloma.
Blake A. Morrison, PharmD, vice president, Medical and Scientific Affairs, Multiple Myeloma Research Foundation, discusses adverse events associated with new agents to treat patients with multiple myeloma. We spoke with Morrison at the 2015 ASH Annual Meeting in December.
New agents such as elotuzumab (Empliciti) and daratumumab (Darzalex)—which were approved in November—seem promising and to have a good overall side effect profile, Morrison says.
There is, however, a risk of infusion reaction with the first exposure. These reactions can be significantly uncomfortable for patients and can be long-lasting, Morrison says. Nurses should be aware of these reactions and look for them when they have a patient in the infusion chair.
Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden
Published: March 19th 2025 | Updated: March 19th 2025Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.
